Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue		$ 371,591	$ 350,207	$ 686,159	$ 630,524
Cost of goods sold		134,075	142,877	243,518	240,635
Gross profit		237,516	207,330	442,641	389,889
General and administrative expense		2,351,696	2,077,973	4,775,347	5,348,750
Operations expense		909,113	567,796	1,800,184	1,142,608
Sales and marketing expense		271,022	159,788	575,489	274,429
Loss on impairment of goodwill		7,231,093	0	7,231,093	0
Total operating loss		(10,525,408)	(2,598,227)	(13,939,472)	(6,375,898)
Other income		41,047	57,033	83,477	85,292
Other expense		(2,217)	(1,829)	(3,206)	(236,801)
Gain (loss) on derivative instruments		95,254	(30,909)	97,162	64,762
Net loss		(10,391,324)	(2,573,932)	(13,762,039)	(6,462,645)
Net loss attributable to common shareholders per common shares-basic and diluted		$ (10,391,324)	$ (2,573,932)	$ (13,762,039)	$ (6,462,645)
Loss per common share basic (in dollars per share)		$ (0.15)	$ (0.05)	$ (0.20)	$ (0.15)
Loss per common share diluted (in dollars per share)		$ (0.15)	$ (0.05)	$ (0.20)	$ (0.15)
Weighted average shared used in computation - basic (in shares)	[1]	68,896,506	51,581,762	67,374,250	44,089,157
Weighted average shared used in computation - diluted (in shares)		68,896,506	51,581,762	67,374,250	44,089,157

[1] The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Six Months ended June 30, 2022 2021 Options 1,035,245 1,013,780 Restricted Stock Units 366,666 325,000 Warrants 36,398,526 31,747,118 Preferred stock: series B 79,246 79,246